Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers

被引:105
作者
Carcangiu, ML
Radice, P
Manoukian, S
Spatti, G
Gobbo, M
Pensotti, V
Crucianelli, R
Pasini, B
机构
[1] Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy
[2] Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy
[3] Ist Nazl Tumori, Dept Prevent & Predict Med, I-20133 Milan, Italy
[4] Ist Nazl Tumori, Gynecol Unit, I-20133 Milan, Italy
[5] FIRC, Inst Mol Oncol, Milan, Italy
关键词
BRCA1; prophylactic salpingo-oophorectomy; fallopian tube; atypical hyperplasia; carcinoma in situ;
D O I
10.1097/01.pgp.0000101082.35393.84
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Although growing numbers of tubal carcinomas in carriers of BRCA1 and BRCA2 germline mutations have been reported, very little is known about the nature and frequency of their possible precursor lesions. The aim of this study is to investigate the occurrence of atypical proliferative tubal lesions in grossly normal fallopian tubes from 26 women with BRCA1 and BRCA2 germline mutations who underwent prophylactic salpingo-ooophorectomy and whose ovaries were histologically negative for carcinoma. Fallopian tubes from 49 women who had undergone hysterectomy with salpingo-oophorectomy for uterine leiomyoma served as controls. In the 22 BRCA1-mutated women, there were two in situ carcinomas and two atypical hyperplasias of the tubal epithelium. The tubes of the BRCA2-mutated women and of the 49 control women did not show any atypical proliferation. The frequency of proliferative lesions of the tubal epithelium, including in situ carcinoma, appears to be increased in BRCA1 mutation carriers. Removal and thorough examination of the fallopian tubes at the time of surgical prophylaxis for ovarian cancer is therefore recommended.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 37 条
[21]  
2-J
[22]   EPITHELIAL HYPERPLASIA OF THE FALLOPIAN-TUBE - ITS ASSOCIATION WITH SEROUS BORDERLINE TUMORS OF THE OVARY [J].
ROBEY, SS ;
SILVA, EG .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1989, 8 (03) :214-220
[23]   Germline BRCA2 mutation in a patient with fallopian tube carcinoma: A case report [J].
Rose, PG ;
Shrigley, R ;
Wiesner, GL .
GYNECOLOGIC ONCOLOGY, 2000, 77 (02) :319-320
[24]   INCIDENCE OF MALIGNANT FALLOPIAN-TUBE TUMORS [J].
ROSENBLATT, KA ;
WEISS, NS ;
SCHWARTZ, SM .
GYNECOLOGIC ONCOLOGY, 1989, 35 (02) :236-239
[25]   Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies [J].
Salazar, H ;
Godwin, AK ;
Daly, MB ;
Laub, PB ;
Hogan, WM ;
Rosenblum, N ;
Boente, MP ;
Lynch, HT ;
Hamilton, TC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (24) :1810-1820
[26]  
Schubert EK, 1997, AM J HUM GENET, V60, P1031
[27]  
Scully RE, 1998, ATLAS TUMOR PATHOLOG
[28]   PRIMARY FALLOPIAN-TUBE ADENOCARCINOMA IN-SITU ASSOCIATED WITH ADJUVANT TAMOXIFEN THERAPY FOR BREAST-CARCINOMA [J].
SONNENDECKER, HEM ;
COOPER, K ;
KALIAN, KN .
GYNECOLOGIC ONCOLOGY, 1994, 52 (03) :402-407
[29]   ATYPICAL EPITHELIAL PROLIFERATIONS IN THE FALLOPIAN-TUBE [J].
STERN, J ;
BUSCEMA, J ;
PARMLEY, T ;
WOODRUFF, JD ;
ROSENSHEIN, NB .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1981, 140 (03) :309-312
[30]   The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [J].
Struewing, JP ;
Hartge, P ;
Wacholder, S ;
Baker, SM ;
Berlin, M ;
McAdams, M ;
Timmerman, MM ;
Brody, LC ;
Tucker, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (20) :1401-1408